Evidence map›Paper›PMID 26111596›Full record

ArticleBiomaterials2015

Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.

S Mishra, D Bedja, C Amuzie, C A Foss, M G Pomper, R Bhattacharya, K J Yarema, S Chatterjee

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Polymeric Nanomaterials for Atherosclerosis Diagnosis and Treatment.Polymer science & technology (Washington, D.C.) · 2025
    Review
  3. How Advanced Is Nanomedicine for Atherosclerosis?International journal of nanomedicine · 2025
    Review
  4. Review
  5. Review
  6. Molecular Pharmacology in Diabetes.International journal of molecular sciences · 2024
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

S Mishra *Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21287, USA.
D Bedja *Department of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.
C Amuzie *Department of Pediatrics, Johns Hopkins University, Baltimore, MD 21287, USA.
C A FossDepartment of Radiology, Johns Hopkins University, Baltimore, MD 21287, USA.
M G PomperDepartment of Radiology, Johns Hopkins University, Baltimore, MD 21287, USA.
R BhattacharyaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21231, USA.
K J YaremaDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21231, USA.
S ChatterjeeDepartment of Pediatrics, Johns Hopkins University, Baltimore, MD 21287, USA.
Johns Hopkins University · US

Funding

Shared Resource CoresP01HL107153 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI KASS, DAVID ALAN · 2011 to 2017
$16.8M
NHLBI NIH HHS P01 HL107153NHLBI NIH HHS P01HL10715301
6 · The paper itself

Abstract

D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), a glycosphingolipid synthesis inhibitor, holds promise for the treatment of atherosclerosis and cardiac hypertrophy but rapid in vivo clearance has severely hindered translation to the clinic. To overcome this impediment, we used a materials-based delivery strategy wherein D-PDMP was encapsulated within a biodegradable polymer composed of poly ethylene glycol (PEG) and sebacic acid (SA). PEG-SA was formulated into nanoparticles that were doped with (125)I-labeled PEG to allow in vivo bio-distribution and release kinetics of D-PDMP to be determined by using γ-scintigraphy and subsequently, by mass spectrometry. Polymer-encapsulation increased the residence time of D-PDMP in the body of a treated mouse from less than one hour to at least four hours (and up to 48 h or longer). This substantially increased in vivo longevity provided by polymer encapsulation resulted in an order of magnitude gain in efficacy for interfering with atherosclerosis and cardiac hypertrophy in apoE-/- mice fed a high fat and high cholesterol (HFHC) diet. These results establish that D-PDMP encapsulated in a biodegradable polymer provides a superior mode of delivery compared to unconjugated D-PDMP by way of increased gastrointestinal absorption and increased residence time thus providing this otherwise rapidly cleared compound with therapeutic relevance in interfering with atherosclerosis, cardiac hypertrophy, and probably other diseases associated with the deleterious effects of abnormally high glycosphingolipid biosynthesis or deficient catabolism.

Indexed as

AnimalsAortic DiseasesApolipoproteins EAtherosclerosisCapsulesCardiomegalyCholesterol, DietaryDecanoic AcidsDelayed-Action PreparationsDicarboxylic AcidsDiet, AtherogenicDrug Evaluation, PreclinicalHeart VentriclesInactivation, MetabolicIodine RadioisotopesLipidsApolipoproteins ECapsulesCholesterol, DietaryDecanoic AcidsDelayed-Action PreparationsDicarboxylic AcidsIodine RadioisotopesLipidsMorpholinesPolyethylene GlycolsRV 538sebacic acidAtherosclerosisBiomaterials-based drug deliveryCardiac hypertrophyGlycosphingolipids

Identifiers

PMID26111596
PMCPMC4557963
OpenAlexW628541189

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.